Literature DB >> 9740612

Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats.

S Otsuka1, M Sugano, N Makino, S Sawada, T Hata, Y Niho.   

Abstract

We administered angiotensin II (Ang II) receptor type 1 (AT1) blockade (losartan, 40 mg x kg-1 x d-1), type II receptor (AT2) blockade (PD123319, 100 mg x kg-1 x d-1), or angiotensin-converting enzyme (ACE) inhibitor (enalapril, 30 mg x kg-1 x d-1) to spontaneously hypertensive rats (SHR) from 10 to 20 weeks of age. Control SHR and Wister-Kyoto rats (WKY) received a placebo for the same period. At the end of treatment, losartan and enalapril were both found to have significantly reduced the arterial systolic blood pressure and the collagen concentration to the level of WKY, whereas PD123319 had no effect. Enalapril and PD123319 significantly reduced the media cross-sectional area of the aorta in comparison to that of untreated SHR, which was still larger than that of the WKY; however, losartan did not change it. Using reverse transcription-polymerase chain reaction, we next examined the mRNA expressions for ACE, AT1 receptor, and AT2 receptor in experimental animals. We observed significantly enhanced mRNA expression for AT1 and AT2 receptors and ACE in untreated SHR compared with WKY. The AT1 mRNA level was also significantly decreased in the SHR treated with either losartan or enalapril, whereas the AT2 mRNA level was significantly decreased in the SHR treated with either PD123319 or enalapril in comparison to untreated SHR. The level of ACE mRNA was significantly decreased only in the SHR treated with enalapril. These results indicate that AT1 receptor, but not AT2 receptor, plays a crucial role in the remodeling of matrix tissue, while AT2 receptor may play a role in the development of hypertrophy of smooth muscle in aorta in SHR, and that the reduction of hypertrophy of smooth muscle does not fully account for the suppression of hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740612     DOI: 10.1161/01.hyp.32.3.467

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

2.  No evidence for angiotensin type 2 receptor gene polymorphism in intron 1 in patients with coarctation of the aorta and Ullrich-Turner syndrome.

Authors:  E Struwe; K Krammer; J Dötsch; M Metzler; H G Dörr; R Cesnjevar; W Rascher; A Koch
Journal:  Pediatr Cardiol       Date:  2006-08-30       Impact factor: 1.655

3.  Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats.

Authors:  Mingyi Wang; Jing Zhang; Gaia Spinetti; Li-Qun Jiang; Robert Monticone; Di Zhao; Linda Cheng; Melissa Krawczyk; Mark Talan; Gianfranco Pintus; Edward G Lakatta
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

4.  Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure.

Authors:  Sarah C Clayton; Karla K V Haack; Irving H Zucker
Journal:  Am J Physiol Renal Physiol       Date:  2010-10-20

Review 5.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

6.  AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR.

Authors:  Xiao C Li; Robert E Widdop
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.